Every 8-K that VENUS CONCEPT INC (VERO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VERO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERO filings page.
Venus Concept Inc. entered into several financing agreements with Madryn Health Partners on January 29, 2026 to address near-term liquidity. A Consent Agreement under the Main Street Priority Loan waives certain minimum liquidity requirements through February 13, 2026 and allows the February 8, 2026 cash interest due under each Note to be applied to principal instead.
The company also signed a Twenty Fifth Bridge Loan Amendment, extending the Bridge Loan maturity date from January 31, 2026 to February 13, 2026, waiving certain minimum liquidity requirements through that date, and increasing the delayed draw commitment from $26,000,000 to $28,000,000. On the same day, Venus Concept completed a Seventeenth Delayed Drawdown of $2,000,000 under the Bridge Financing, which bears interest at 12% per year. The company plans to use net proceeds for general working capital needs.
Venus Concept Inc. has entered into short-term financing amendments and decided to leave the public markets. On January 14, 2026, the company and its subsidiaries signed a Consent Agreement with Madryn lenders waiving certain minimum liquidity requirements under its Main Street Priority Loan through January 31, 2026. The same day, they executed a Twenty Fourth Bridge Loan Amendment extending the Bridge Loan maturity from January 14, 2026 to January 31, 2026 and waiving related minimum liquidity requirements through that date.
On January 20, 2026, the board approved a plan to voluntarily delist the company’s common stock from the Nasdaq Capital Market, deregister under U.S. securities laws, and suspend SEC reporting. Venus Concept plans to file Form 25 on or about January 30, 2026, with delisting and deregistration under Section 12(b) expected to become effective on or about February 6, 2026, when Nasdaq trading will cease. It then expects to file Form 15 to suspend periodic reporting, with Exchange Act registration terminating permanently 90 days later. The company cites public-company costs, low trading volumes, and regulatory burdens, and expects meaningful annual cost savings from this move.
Venus Concept Inc. reports new agreements with its lenders that provide short-term covenant relief and extend a key loan maturity. On December 31, 2025, the company and its subsidiaries entered into a Consent Agreement under the Main Street Priority Loan, waiving certain minimum liquidity requirements through January 14, 2026. The borrower is also allowed to apply the January 8, 2026 cash interest payment due under each note to reduce the principal balance instead of paying cash interest. The same day, the parties signed a Twenty Third Bridge Loan Amendment that pushes the bridge loan maturity date from December 31, 2025 to January 14, 2026 and waives certain minimum liquidity requirements over the same period.
Venus Concept Inc. reported two developments. The company furnished a press release with its financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1. The company states this information is provided under Item 2.02 and “shall not be deemed filed” under the Exchange Act.
Separately, Venus Concept announced it received U.S. FDA 510(k) clearance to market Venus Nova, a new multi-application platform for non-invasive body and skin treatments. A press release regarding the clearance is attached as Exhibit 99.2 and is incorporated by reference. These updates reflect recent operating and regulatory milestones disclosed via an 8-K.
Venus Concept (VERO) announced new lender consents and amendments to its debt facilities to manage near‑term liquidity. The company obtained a waiver of certain minimum liquidity requirements under both its Main Street Priority Loan and Bridge Loan through November 30, 2025. The Bridge Loan maturity was also extended to November 30, 2025.
The lenders permitted Venus USA to apply the November 8, 2025 cash interest payment due under each Note to the principal balance of each Note. Separately, the company received a $2,000,000 draw on October 28, 2025 under its Bridge Financing, which bears interest at 12% per annum, and expects to use the proceeds, after transaction expenses, for general working capital. The Bridge Financing’s aggregate principal capacity was previously increased to $28,237,906.85 secured by a priority security interest in the Loan Parties’ collateral.
Venus Concept Inc. entered agreements to convert a secured subordinated convertible note held by Madryn and to amend related financing and registration arrangements. The company agreed to exchange the existing secured subordinated convertible note dated June 30, 2025 with an original principal of $4,105,696.60 for 201,774 shares of newly designated Series Y Convertible Preferred Stock. The filing lists several related documents, including a Certificate of Amendment for the Series Y preferred, an Exchange Agreement, a Registration Rights Agreement, a Consent Agreement, and a Bridge Loan Amendment, plus a press release.
The filings indicate the company and Madryn agreed to restructure the note into preferred equity and to amend registration and bridge loan terms, with accompanying documentary updates reflecting those changes.
Venus Concept Inc. reports another borrowing under its existing bridge loan with Madryn Health Partners. On September 19, 2025, the lenders funded a “Twelfth Delayed Drawdown” term loan of $2,000,000 under the Loan and Security Agreement, which provides for up to $23,237,906.85 in aggregate principal at a 12% annual interest rate, secured by a priority interest in the loan parties’ real and personal property. The company plans to use the new funds, after transaction expenses, for general working capital.
The board also approved transaction completion bonuses for Rajiv De Silva and Domenic Della Penna, payable in cash or cash equivalents upon completion of a defined Strategic Transaction that results in a change of control. Mr. De Silva’s potential bonus ranges from $715,000 to approximately $2.12 million, and Mr. Della Penna’s ranges from $338,000 to approximately $1 million. Payment requires successful completion of the transaction within the specified period and that each awardee remains a full-time employee in good standing on the payment date.
Venus Concept Inc. disclosed that on August 31, 2025 its U.S., Canadian and Israeli subsidiaries and the parent entered into multiple lender agreements providing temporary relief around liquidity and loan timing. A Consent Agreement with Madryn lenders waived certain minimum liquidity requirements under the Main Street Priority Loan through September 30, 2025. A Nineteenth Bridge Loan Amendment extended the Bridge Loan maturity from August 31, 2025 to September 30, 2025. A separate Notes Consent Agreement waived certain minimum liquidity requirements under the secured subordinated convertible notes issued March 31, 2025 through September 30, 2025. Copies of each agreement are filed as Exhibits 10.1–10.3.
Venus Concept Inc. obtained an additional $2,000,000 under its existing bridge term loan with Madryn Health Partners on August 21, 2025. This eleventh delayed drawdown is part of a secured Bridge Financing facility that has been increased to an aggregate principal amount of up to $23,237,906.85 and bears interest at 12% per year.
The loan is secured by a priority security interest in substantially all real and personal property of the participating subsidiaries. Venus Concept expects to use the new proceeds, after transaction expenses, for general working capital needs.
Venus Concept Inc. filed a Form 8-K disclosing that on August 14, 2025 the company issued a press release reporting its financial results for the three and six months ended June 30, 2025. The press release is attached to the current report as Exhibit 99.1. The 8-K states that the information in Item 2.02 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference except by specific reference in a future filing. No financial figures or operational details are included in the text provided here.
Venus Concept (Nasdaq: VERO) filed an 8-K detailing the June 25, 2025 Annual & Special Meeting results.
Key outcomes:
- Shareholders authorized the issuance of up to 11.3 million common shares upon conversion of existing Series Y, Series X, Senior Convertible Preferred Stock and 2025 secured notes.
- All three Class II directors—Louise Lacchin, Anthony Natale M.D. and Stanley Tyler Hollmig M.D.—were re-elected.
- MNP LLP was ratified as independent auditor for FY 2025.
The approvals eliminate contractual share-cap restrictions, enabling conversions that could materially expand the public float while extinguishing preferred obligations and related cash interest. No other material items were reported.